Literature DB >> 25400734

Immunological response of recombinant H. pylori multi-epitope vaccine with different vaccination strategies.

Baoning Wang1, Xing Pan2, Hongren Wang1, Yongjun Zhou3, Jie Zhu3, Jing Yang2, Wanyi Li1.   

Abstract

OBJECTIVE: To investigate different protective effects of recombinant H. pylori multi-epitope antigen (rIB) with cholera toxin subunit B (rCTB) as the intramolecular/extramolecular adjuvant though different immunization routes in a Helicobacter pylori infected mouse model.
METHODS: By using rCTB as the intramolecular/extramolecular adjuvant of rIB, BALB/c mice were immunized through oral administration or intramuscular injection, on day 0, 14, 28. Every 14 days, ELISA was used to detect serum specific IgG and IgA titers after immunization. After the last immunization, H. pylori SS1 challenge was performed, and urease test, Gram staining after smearing of mouse gastric tissue, PCR, pathology and immunohistochemistry were used to evaluate preventive effect of the recombinant protein vaccine.
RESULTS: After immunization three times, intramolecular injection could induce high titers of serum specific IgG antibody, and the antibody titer in rIB group, rCTB+rIB and rBIB group was 2000, 5000 and 7500, respectively (P < 0.05). Specific IgA antibody was only detected in rBIB oral administration group. The immune protection rate in rBIB oral administration group was significantly higher than that in rBIB intramolecular injection group (33.3% vs. 83%), indicating significant difference.
CONCLUSION: rCTB has good intramolecular/extramolecular immune adjuvant effects, and its intramolecular immune adjuvant effect is better. Both intramolecular injection and oral administration of rBIB have immune protective effect against H. pylori challenge, and oral administration of rBIB exerts better immune protective effect.

Entities:  

Keywords:  Helicobacter pylori; adjuvant; cholera toxin subunit B; immunological response; recombinant vaccine

Mesh:

Substances:

Year:  2014        PMID: 25400734      PMCID: PMC4230088     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  8 in total

1.  Moving Helicobacter pylori vaccine development forward with bioinformatics and immunomics.

Authors:  Leonard Moise; Steven F Moss; Anne S De Groot
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

Review 2.  Advances in vaccination against Helicobacter pylori.

Authors:  Dominique Velin; Pierre Michetti
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-04       Impact factor: 3.869

Review 3.  Histologic scoring of gastritis and gastric cancer in mouse models.

Authors:  Arlin B Rogers
Journal:  Methods Mol Biol       Date:  2012

Review 4.  The current status of Helicobacter pylori vaccines: a review.

Authors:  Shahjahan Kabir
Journal:  Helicobacter       Date:  2007-04       Impact factor: 5.753

5.  [Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study].

Authors: 
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2004-07-17

6.  Immunological features and efficacy of the reconstructed epitope vaccine CtUBE against Helicobacter pylori infection in BALB/c mice model.

Authors:  Le Guo; Kunmei Liu; Wenfeng Zhao; Xiaokang Li; Tong Li; Feng Tang; Rui Zhang; Wutong Wu; Tao Xi
Journal:  Appl Microbiol Biotechnol       Date:  2012-10-13       Impact factor: 4.813

Review 7.  Development of vaccines against Helicobacter pylori.

Authors:  Giuseppe Del Giudice; Peter Malfertheiner; Rino Rappuoli
Journal:  Expert Rev Vaccines       Date:  2009-08       Impact factor: 5.217

Review 8.  Inflammation, immunity, and vaccines for Helicobacter pylori infection.

Authors:  Alojz Ihan; Irina V Pinchuk; Ellen J Beswick
Journal:  Helicobacter       Date:  2012-09       Impact factor: 5.753

  8 in total
  3 in total

Review 1.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

2.  An engineered food-grade Lactococcus lactis strain for production and delivery of heat-labile enterotoxin B subunit to mucosal sites.

Authors:  Nan Sun; Rongguang Zhang; Guangcai Duan; Xiaoyan Peng; Chen Wang; Qingtang Fan; Shuaiyin Chen; Yuanlin Xi
Journal:  BMC Biotechnol       Date:  2017-03-06       Impact factor: 2.563

Review 3.  Pathogenesis and clinical management of Helicobacter pylori gastric infection.

Authors:  Breno Bittencourt de Brito; Filipe Antônio França da Silva; Aline Silva Soares; Vinícius Afonso Pereira; Maria Luísa Cordeiro Santos; Mariana Miranda Sampaio; Pedro Henrique Moreira Neves; Fabrício Freire de Melo
Journal:  World J Gastroenterol       Date:  2019-10-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.